PT - JOURNAL ARTICLE AU - Zheutlin, Amanda B AU - Vieira, Luciana AU - Li, Shilong AU - Wang, Zichen AU - Schadt, Emilio AU - Gross, Susan AU - Stone, Joanne AU - Schadt, Eric AU - Li, Li TI - Improving postpartum hemorrhage risk prediction using longitudinal electronic medical records AID - 10.1101/2021.03.16.21253746 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.16.21253746 4099 - http://medrxiv.org/content/early/2021/03/20/2021.03.16.21253746.short 4100 - http://medrxiv.org/content/early/2021/03/20/2021.03.16.21253746.full AB - Objective Postpartum hemorrhage (PPH) remains a leading cause of preventable maternal mortality in the US. Our goal was to develop a novel risk assessment tool and compare its accuracy to those used in current practice.Materials and Methods We used a PPH digital phenotype we developed and validated previously to identify 6,639 cases from our delivery cohort (N=70,948). Using a vast array of known and potential risk factors extracted from electronic medical records available prior to delivery, we trained a gradient boosting model in a subset of our cohort. In a held-out test sample, we compared performance of our model to three clinical risk tools and one previously published model.Results Our 24-feature model achieved an area under the curve (AUC) of 0.71 (95% confidence interval [CI], 0.69-0.72), higher than all other tools (research-based AUC: 0.67 [95%CI, 0.66-0.69], clinical AUCs: 0.55 [95%CI, 0.54-0.56] to 0.61 [95%CI, 0.59-0.62]). Five features were novel including red blood cell indices and infection markers measured standardly upon admission. Additionally, we identified inflection points for several vital signs and labs where risk rose substantially. Most notably, patients with median intrapartum systolic blood pressure above 132mmHg had an 11% [interquartile range, 4%] median increase in relative risk for PPH.Conclusions We developed a novel approach for predicting PPH and identified clinical feature thresholds that can guide intrapartum monitoring for PPH risk. Our results suggest our model is an excellent candidate for prospective evaluation and could ultimately reduce PPH morbidity and mortality through early detection and prevention.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this study was provided by Sema4, a health intelligence company.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We received approval from the Icahn School of Medicine at Mount Sinai Institutional Review Board (IRB-17-01245) to conduct this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData cannot be shared for ethical/privacy reasons.